KR101667496B1 - Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising Weissella cibaria WIKIM28 as active ingredient - Google Patents
Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising Weissella cibaria WIKIM28 as active ingredient Download PDFInfo
- Publication number
- KR101667496B1 KR101667496B1 KR1020150159014A KR20150159014A KR101667496B1 KR 101667496 B1 KR101667496 B1 KR 101667496B1 KR 1020150159014 A KR1020150159014 A KR 1020150159014A KR 20150159014 A KR20150159014 A KR 20150159014A KR 101667496 B1 KR101667496 B1 KR 101667496B1
- Authority
- KR
- South Korea
- Prior art keywords
- atopic dermatitis
- wikim28
- composition
- present
- cells
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 43
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 43
- 241000975185 Weissella cibaria Species 0.000 title claims abstract description 25
- 239000004480 active ingredient Substances 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 230000002265 prevention Effects 0.000 title description 6
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 102000004127 Cytokines Human genes 0.000 claims abstract description 22
- 108090000695 Cytokines Proteins 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 6
- 239000002537 cosmetic Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000006210 lotion Substances 0.000 claims description 12
- 102000004388 Interleukin-4 Human genes 0.000 claims description 10
- 108090000978 Interleukin-4 Proteins 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 210000003289 regulatory T cell Anatomy 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 9
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 108010002616 Interleukin-5 Proteins 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 108090000176 Interleukin-13 Proteins 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 230000031261 interleukin-10 production Effects 0.000 claims description 3
- 239000004902 Softening Agent Substances 0.000 claims description 2
- 208000030961 allergic reaction Diseases 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 34
- 241000894006 Bacteria Species 0.000 abstract description 17
- 239000004310 lactic acid Substances 0.000 abstract description 17
- 235000014655 lactic acid Nutrition 0.000 abstract description 17
- 235000021109 kimchi Nutrition 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 description 17
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 206010003645 Atopy Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 208000017520 skin disease Diseases 0.000 description 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- -1 foundation Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000011703 D-panthenol Substances 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 235000004866 D-panthenol Nutrition 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 241000202221 Weissella Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229960003949 dexpanthenol Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 102000004201 Ceramidases Human genes 0.000 description 1
- 108090000751 Ceramidases Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940020485 elidel Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000018711 interleukin-13 production Effects 0.000 description 1
- 230000022023 interleukin-5 production Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000019079 negative regulation of cytokine secretion Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000004466 pelleted feed Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940112971 protopic Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
Description
The present invention relates to a pharmaceutical composition for preventing or treating atopic dermatitis comprising, as an active ingredient, Weissella cibaria ( WIKIM28, KFCC11526P) which is a lactic acid bacterium extracted from kimchi.
Atopic dermatitis is a disease in which the skin becomes irritated by chronic irritation of the skin due to irritating factors that are not harmful to normal people. In other words, it is known that the atopic dermatitis is caused by an immune system overexpression in a specific substance such as an infection caused by bacteria, viruses, fungi, pollen, etc., food, artificial chemical substances.
These immune responses involve T cells. It is known that the imbalance between two types of cytokines, Th1 cytokine and Th2 cytokine, secreted by T cells plays an important role in the pathogenesis of atopic dermatitis. Typical Th1 cytokines include interferon gamma (IFN-gamma, IFN-gamma) and are involved in cell-mediated immune responses. Th2 cytokines are characterized by overexpression of Th2 cytokines such as interleukin-4 (Tang ML., etc., Interleukin-4 and interferone-γ production in atopic and non-atopic children with asthma. Clin Exp Allergy 1995; 25: 515-21).
In addition, the skin of most patients with atopic dermatitis has a very high concentration of staphylococci, which is approximately 10 7 CFU / cm 2 , 200 times higher than normal. Because of these bacteria, immunoglobulin E (IgE) is continuously produced, and the ceramidase secreted by these bacteria decomposes ceramide, which maintains the subcutaneous moisturizing ability, to continuously induce itching, . Because IL-4, a Th2 cytokine, facilitates the attachment of these bacteria to the skin, once the atopic dermatitis occurs, the staphylococci grow prominently (Donald YM, et al., Infection in atopic dermatitis. Curr Opin Pediatr 2003; 15: 399-404 and Chos SH, et al., Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol 2001; 116: 658-63).
The standard treatment for these atopic dermatitis is immunosuppressive agents and biological response modifiers (BRM). Immunosuppressants include steroids or chalconein inhibitors (tacrolimus, Protopic TM , or pimecrolimus, Elidel TM ), and interferon gamma and antihistamine are examples of regulators of biological reactions, but they have the effect of temporarily alleviating the symptoms, but in patients with long-term use of external or oral steroid hormones, The development of osteoporosis and the development of osteoporosis in children. Therefore, it may be a clinical problem due to local and systemic side effects such as growth inhibition. In severe cases, systemic symptoms due to hormones may appear. It may also show resistance to steroids Thus, a situation where the development of new therapeutic agents for atopic fewer side effects while having an excellent effect in the treatment of eczema natural origin is required.
Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made keeping in mind the above problems occurring in the prior art, and an object of the present invention is to provide a method for treating atopic dermatitis, comprising fermenting a herb medicine, And / or a composition for prevention.
It is also an object of the present invention is derived from Kimchi lactic acid bacteria having a therapeutic effect on atopic dermatitis and this Cellar cibaria (Weissella cibaria , WIKIM28, KFCC11625P).
More specifically, the technical problem to be solved by the present invention is to suppress the excessive production of IL-4, IL-5 and IL-13 mediating the immunoregulatory mediator, IgE hyperadhesive or IgE response, -10 A composition for treating or improving atopic dermatitis comprising lactic acid bacteria that improves the secretion of cytokines.
However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.
Hereinafter, various embodiments described herein will be described with reference to the drawings. In the following description, for purposes of complete understanding of the present invention, various specific details are set forth, such as specific forms, compositions and processes, and the like. However, certain embodiments may be practiced without one or more of these specific details, or with other known methods and forms. In other instances, well-known processes and techniques of manufacture are not described in any detail, in order not to unnecessarily obscure the present invention. Reference throughout this specification to "one embodiment" or "embodiment" means that a particular feature, form, composition, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Accordingly, the appearances of the phrase " in one embodiment "or" an embodiment "in various places throughout this specification are not necessarily indicative of the same embodiment of the present invention. In addition, a particular feature, form, composition, or characteristic may be combined in any suitable manner in one or more embodiments.
In one embodiment according to the present invention, weissella cibaria , WIKIM28, KFCC11625P). The present invention also provides a pharmaceutical composition for preventing or treating skin diseases. In this embodiment, the composition promotes or increases the activity of regulatory T cells (Tregs) by promoting the production of cytokines IL-10 and inhibits the activity of any one of IL-4, IL-5 and IL- The present invention provides a pharmaceutical composition for the prevention or treatment of skin diseases, which is characterized by down-regulating cytokine to reduce the allergic reaction and inhibiting the hypersensitive inflammatory reaction by inhibiting IgE production.
In one embodiment of the present invention, the skin disease is associated with atopy, psoriasis, eczema, keratosis, ovarian or water warts, but is not limited to, any one of IL-4, IL-5 and IL- It is known that there is a reduction effect such as treatment or prevention when the cine is down-regulated. In particular, atopic dermatitis is known to have a remarkable effect (Romagnani, S. Type T helper and type II helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 1991; 21: 152-158 Kim JY, et al., Atopic dermatitis-mitigating effects of new Lactobacillus strain, Lactobacillus sakei probiotic 65 isolated from Kimchi. Journal of Applied Microbiology 2013; 115: 517-526). In contrast, IL-10 is a cytokine secreted by various immune cells (dendritic cells, T cells, B cells, macrophages, regulatory T cells, etc.) (Cezmi, A., et al., "Mechanisms and treatment of allergic diseases"). J Allergy Clin Immunol 2006; 123: 735-746 and Ouyang W. et al., Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011; 29: 71-109). In addition, atopic dermatitis is used to include all diseases classified as atopic dermatitis in the art regardless of the direct or indirect cause of the occurrence thereof. In general, atopic dermatitis is classified into infantile atopic dermatitis, pediatric atopic dermatitis, adult atopic dermatitis and mothergic atopic dermatitis according to the onset or the onset of the onset. In the present invention, atopic dermatitis includes all types of atopic dermatitis .
In another embodiment according to the present invention, weissella cibaria , WIKIM28, KFCC11625P) as an active ingredient. In the above embodiment, the skin disease is any one selected from the group consisting of atopy, psoriasis, eczema, eczema, and water warts, and provides a cosmetic composition for alleviating and improving skin diseases. In the above-mentioned embodiments, the cosmetic composition is formulated into a formulation selected from the group consisting of cream, softening lotion, convergent lotion, milk lotion, foundation, soap and cleansing foam. Respectively.
In another embodiment according to the present invention, there is provided a food composition for alleviating or ameliorating skin diseases comprising Weissella cibaria ( WIKIM28, KFCC11625P). In the above embodiment, the skin disease is any one selected from the group consisting of atopy, psoriasis, eczema, keratosis, ovulation, and water warts.
Unless defined otherwise in the specification, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
According to one embodiment of the present invention, a clinical visual evaluation method generally used in atopic dermatitis includes erythema, pruritus and dry skin, edema & excoriation, erosion, ) And lichenification were evaluated. The sensory evaluation was performed by summing the scores of five items. As a result, when the kimchi-derived lactic acid bacteria according to the present invention were administered, the skin severity score tended to decrease, and in particular, When the kimchi-derived lactic acid bacteria of the present invention were administered, the skin severity score was significantly decreased.
The present invention also provides a health food for prevention or alleviation of atopic dermatitis comprising Kimchi-derived lactic acid bacteria, such as Weissella cibaria ( WIKIM28, KFCC11625P). The lactic acid bacteria derived from Kimchi of the present invention can be added to health food for the purpose of improving atopic dermatitis. When used as a food additive, it can be used as it is or can be used together with other food or food ingredients, Can be used. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). There is no particular limitation on the kind of the food, and it includes all the health foods in the ordinary sense.
In addition to the health food, the food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pet acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, , Carbonating agents used in carbonated beverages, and the like. Although the proportion of the additive is not critical, it is generally selected in the range of 0.01 to 0.1 part by weight per 100 parts by weight of the active ingredient.
The formulation of the cosmetic composition of the present invention is not particularly limited, but it is preferably a formulation of an external preparation for skin. One preferred form of the composition for external application of the skin is a softener, a nutritional lotion, a massage cream, A cosmetic composition having a formulation of an adhesive type cosmetic composition, and another preferred form is a transdermal dosage form such as lotion, ointment, gel, cream, patch or spray. Further, in the external preparation for each formulation, components other than the above-mentioned essential components can be mixed and selected without difficulty by those skilled in the art depending on the formulation or purpose of use of the other external preparation.
The cosmetic composition of the present invention preferably contains a cosmetically acceptable medium or base. It may be any formulation suitable for topical application, for example, as a solution, a gel, a solid or a paste anhydrous product, an emulsion obtained by dispersing an oil phase in a water phase, a suspension microemulsion, a microcapsule, a microgranule or an ionic form (liposome) In the form of a warm follicular dispersion, or in the form of creams, skins, lotions, powders, ointments, sprays or conical sticks. It can also be prepared in the form of a foam or an aerosol composition further containing a compressed propellant. In addition, the cosmetic compositions of the present invention can be prepared in the form of adjuvants which can be applied topically or systemically, which are conventionally used in the field of dermatology by containing dermatologically acceptable mediums or bases, Can be prepared according to the method.
In addition, the cosmetic composition of the present invention can be used as a cosmetic composition in the form of a cosmetic composition containing a lipid, an organic solvent, a solubilizer, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, In the field of cosmetics such as fillers, sequestering and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredient commonly used in cosmetics And may contain commonly used adjuvants. These adjuvants are introduced in amounts commonly used in the cosmetics field.
The composition of the present invention can be formulated in the form of a liquid, an aerosol, and a sterile injectable solution. When the composition is formulated, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, Can be used.
Hereinafter, the present invention will be described in detail.
The kimchi-derived lactic acid bacterium Weissella cibaria , WIKIM28, KFCC11625P) showed excellent effects in the treatment and / or amelioration of atopic dermatitis as compared with the conventional treatment for atopic dermatitis, and the composition for treating atopic dermatitis according to the present invention is related to the exogenous atopic dermatitis And has a superior effect of treating and / or improving atopy by controlling the secretion of cytokines from immune T cells.
FIG. 1 is a graph showing the area showing erythema and alleviation of skin scar formation when the composition according to the present invention is administered to a mouse.
FIG. 2 is a graph showing the inhibitory effect of the composition according to the present invention on the serum IgE production when administered to mice, wherein * (P <0.05) is a comparison between the Naive normal group and the DNCB control group, ** (P <0.05) DNCB control group and Kerotifen treatment group (positive control group) or WIKIM28 treatment group (experimental group).
FIG. 3 is a graph showing the inhibition of cytokine secretion when the composition of the present invention was administered to a mouse. * (P <0.05) is a comparison between the Naive normal group and the DNCB control group, and ** (P <0.05) DNCB control group and Kerotifen treatment group (positive control group) or WIKIM28 treatment group (experimental group).
FIG. 4 shows the results of the production of cytokine IL-10 from mesenteric lymph node cells when the composition of the present invention was administered to mice. * (P <0.1) was compared between DNCB control group and WIKIM28 treatment group Results.
FIG. 5 shows the results of cytokine IL-10 production from spleen immunocytes when the composition of the present invention was administered to mice. * (P <0.1) is the result of comparing -OVA with + OVA ** P <0.05) is the result of comparing STD with WIKIM28.
Hereinafter, the present invention will be described in more detail with reference to Examples. It will be apparent to those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
Isolation and culture
The present inventors purchased kimchi lactic acid bacteria from kimchi by purchasing an optimum fermented Doshan mustard kimchi. The Kimchi samples were crushed, filtered, diluted 10 6 to 10 9, and cultured in Lactobacilli MRS (Difco) agar medium for more than 24 hours. After colony formation, cultivated colonies were selected and cultured. Five different strains of lactic acid bacteria were screened through acquired immune response experiment and finally identified by 16S RNA sequencing. Accept that one of the excellent effect of Lactobacillus species from the World Institute of Kimchi microbial gene banks given a unique number WIKIM28 was named Wai Cellar Sheba Leah (Weissella cibaria) WIKIM28. The strains isolated from kimchi were cultured for 24 hours at 30 ° C in MRS medium. Cells were centrifuged at 8,000 rpm for 5 minutes to remove the culture medium and washed with PBS (Phosphate Buffered Saline) solution to remove the remaining medium Respectively.
The strains isolated from kimchi were cultured for 24 hours at 30 ° C in MRS medium. The cells were centrifuged at 8,000 rpm for 5 minutes to remove the culture medium and washed with PBS (Phosphate Buffered Saline) to remove the remaining medium Respectively.
Experimental animal
A 5-week-old male Balb / c mouse (Orient Bio, Korea) was supplied to the experimental animal. The animals were kept in the SPF environment at room temperature of 20 ± 2 ° C and humidity of 55 ± 15% The animals were raised during the experimental period. Feeds were fed with common pelleted feed without antibiotics, and water was ingested at frequent intervals.
atopy Abatement effect
3-1. Atopic dermatitis induction and Wyse Shivaire ( Weissella cibaria ) WIKIM28 process
One day prior to the application of the stimulant substance 2,4-dinitrochlorobenzene (DNCB) to the experimental animals, hair was removed from the back of the experimental animals to the pelvis in an area of 2 x 4 cm. 1% DNCB was dissolved in a solvent (acetone: olive oil = 4: 1) and applied to the dorsal epidermis on
After 4 weeks of oral administration of the lactic acid bacteria of the present invention (Wyselashibaria, WIKIM28), the appearance of dermatitis was evaluated by clinical visual evaluation. In the control group treated with DNCB compared to the normal group, erythema, erythema and scarring, which are the criteria for sensory evaluation, can be confirmed. These symptoms are caused by the antihistamine kerotifen treated with the positive control and the lactic acid bacteria Weissella When cibaria WIKIM28 was administered, it was confirmed that the areas showing erythema and the skin scar formation were alleviated (Fig. 1).
3.2 Serum IgE Measure
It is known that IgE reacts with mast cells or eosinophils to stimulate secretion of histamine and other inflammatory substances. It is known that allergic inflammatory diseases such as atopy increase its level more than normal. It is used as a marker of dermatitis. After 6 weeks of experiment, mice were sacrificed for 43 days and the amount of IgE production in the blood was measured.
Blood was collected from the animal through venipuncture, and the plasma separated from the blood was stored in a -80 ° C freezer until use. Serum IgE was quantitated by ELISA method to compare the level of IgE present in plasma. 2 μg / ml (100 μl per mouse) of mouse IgE antibody (BD Pharmingen, San Diego, Calif.) Was added to Immulon 2 plate (Dynex, Chantilly, VA) , The diluted plasma and standard IgE standards (BD Pharmingen) were added and reacted at room temperature for 2 hours. Then, biotinylated anti-mouse IgE and streptavidin-HRP (1 μg /
In the control group treated with DNCB, the production of IgE was promoted at 875 ng / ml compared to that of Naive normal group. However, the positive control group, kerotifen and WIKIM28, showed a significant inhibition of IgE production by about 26% (649 ng / ml) and about 55% (395 ng / ml) (Fig. 2). ≪ tb > < TABLE >
3.3 Mouse spleen immunocyte culture and cytokine production assay
After creating a single group of cells were collected from the mouse the spleen was dispensed anti -CD3 / CD28 monoclonal antibody per
Similar to the inhibition of serum IgE production, the cytokines IL-4, IL-5 and IL-13 secreted in spleen immunocytes activated by anti-CD3 / CD28 monoclonal antibodies were approximately 70 (IL-4), about 65% (IL-5) and about 70% (IL-13). These results suggest that the administration of WIKIM28 inhibits the response of Th2 cells, suggesting that DNCB may reduce the Th2 - biased allergic response.
3.4 Mouse Mesenteric Lymph Node Immune Cell Culture and Cytokine Generation Analysis
IL-10 is a cytokine secreted by regulatory T cells and is known to be involved in anti-inflammatory and immune response mitigation by modulating the Th1 / Th2 response. Mesenteric lymph nodes were collected from the mice to prepare a single cell group. 5 × 10 5 cells / well were dispensed into a 96-well plate coated with anti-CD3 / CD28 monoclonal antibody (1 μg / well, BD Pharmingen) After culturing in a 5% CO 2 incubator for 24 hours, cell culture medium was recovered and cytokine IL-10 production was measured by cytometric bead array (BD Pharmingen). The production of cytokine IL-10 was significantly increased in the experimental group treated with WIKIM28 (FIG. 4). These results indicate that administration of WIKIM28 as a different response to the positive control, Kerotifen, induces the activity of regulatory T cells and alleviates symptoms of atopic dermatitis.
Evaluation of acquired immune modulating effect
To investigate antigen-specific acquired immune modulating effects, WIKIM28, which was treated with OVA-sensitized Th2-responsive mouse spleen cells, and a homologous lactic acid bacterium Weissella cibaria , KCCM 41287) were co-cultured to evaluate the production promoting ability of IL-10, which is a regulatory T cell response-inducing cytokine.
4-1. Lactic acid Quartz
The same subordinate to WIKIM28 of the present invention, < RTI ID = 0.0 > Weissella & cibaria , KCCM 41287, STD) were performed to compare and evaluate the immunostimulatory effect produced by the strain. After culturing in MRS medium (Difco) at 30 ° C for 24 hours, the cells were centrifuged and washed with saline (PBS) 2-3 times to remove the remaining medium. Bacterial counts were measured by serial dilution and each strain was quantitated at 1 × 10 9 CFU / ml. Then, heat was applied at 95 DEG C for 30 minutes to perform quenching.
4-2. OVA Sensitization Spleen immune cell culture and cytokine analysis of mouse
To induce OVA allergy sensitization to male Balb / c mice at 6 weeks of age, 200 μl of a solution of 1 mg OVA, Imject Alum (Thermo Scientific) and PBS was sensitized by intraperitoneal administration twice per 7 days. That the after day 14 after the after harvesting the spleen from mice sensitized to OVA single cell population made adjustment per well 55 cells in a 96 well plate again stimulated with 200 ㎍ / ㎖ OVA and use disproportionated concurrently 1 7 CFU WIKIM28 or four The cells were cultured for 24 h at 37 ° C in a 5% CO 2 incubator at 37 ° C and treated with homogenized 17 CFU of Weissella cibaria (KCCM 41287). The amount of IL-10 cytokine produced was measured by cytometric bead array BD Pharmingen).
WIKIM28 showed that the production of IL-10 was increased about 30% in + OVA in which OVA was co-cultured compared to -OVA in which OVA was not co-cultured (Fig. 5, left). Further, the same kind of lactic acid bacteria and this Cellar cibaria (Weissella cibaria , KCCM 41287, STD), it was confirmed that the production of IL-10 was increased by about 26% by WIKIM28 (right side of FIG. 5). This result shows that WIKIM28 is more effective in inducing the activity of regulatory T cells even in the same kind of lactic acid bacteria.
Formulation Example 1. Preparation of injection
(2 ml) per 1 ampoule in accordance with the usual injection preparation method.
Formulation Example 2. Preparation of cosmetic preparation
2.1 Softening life (content:% by weight)
In the comparative example, leuconostocite (WIKIM28) is absent and 0.3 wt% of triclosan is added.
2.2 Lotion (content:% by weight)
2.3 Nourishing lotion (content:% by weight)
(Weissella cibaria, WIKIM28)
2.4 Nourishing Cream (Content:% by weight)
(Weissella cibaria, WIKIM28)
2.5 Massage Cream (Content:% by weight)
(Weissella cibaria, WIKIM28)
2.6 packs (content:% by weight)
(Weissella cibaria, WIKIM28)
Although the invention has been described in detail with reference to a preferred method, other embodiments, adaptations and variations are possible within the scope of the invention.
The pharmaceutical composition according to the present invention may be administered orally or parenterally depending on various factors including the activity of the specific compound used, age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, And the dose of the pharmaceutical composition varies depending on the condition of the patient, the body weight, the degree of disease, the type of drug, the route of administration and the period of time, but may be appropriately selected by a person skilled in the art and is preferably from 0.0001 to 50 mg / Kg or 0.001 to 50 mg / kg. The administration may be carried out once a day or divided into several doses. The dose is not intended to limit the scope of the invention in any way. The pharmaceutical compositions according to the present invention can be formulated into pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions. For example, in the case of oral administration, it is not particularly limited as long as it can be applied in the oral cavity, and an excipient, a binder, a disintegrating agent or other suitable additives may be added to the tablet, , Ointments such as syrups, rimonadzes, retentive, emulsifiable or water-soluble types, jellies, liquids, elixirs, suspensions, emulsions, troches and the like. In the case of long-term continuous administration of various dosage forms, it is preferable that the administration site is made into the skin in the form of a percutaneous administration agent such as a patch or the like, since the persistence of the administration site is enhanced by the western effect, , And is particularly preferable because it is easy to stably administer an effective amount for a long period of time.
All references, articles, publications and patents and patent applications cited herein are hereby incorporated by reference in their entirety. Accordingly, the spirit and scope of the following claims should not be limited to the description of the preferred embodiments described above.
Name of depository: Korea Microorganism Conservation Center (Domestic)
Accession number: KFCC11625P
Checked on: 2015108
Claims (15)
Wherein said composition promotes or increases the activity of regulatory T cells (Tregs).
Wherein the promoting or increasing activity of the regulatory T cells is by promoting cytokine IL-10 production.
Wherein the composition is used to down-regulate cytokine expression in T cells to reduce an allergic reaction.
Wherein said cytokine is any one of IL-4, IL-5 and IL-13.
Wherein said composition inhibits hypersensitivity inflammatory reaction by inhibiting IgE production. ≪ RTI ID = 0.0 > 8. < / RTI >
Wherein the cosmetic composition is formulated into a formulation selected from the group consisting of a cream, a softening agent, a convergent lotion, a milk lotion, a foundation, a soap and a cleansing foam.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150144195 | 2015-10-15 | ||
| KR20150144195 | 2015-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101667496B1 true KR101667496B1 (en) | 2016-10-18 |
Family
ID=57244172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150159014A KR101667496B1 (en) | 2015-10-15 | 2015-11-12 | Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising Weissella cibaria WIKIM28 as active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101667496B1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101801697B1 (en) | 2016-12-12 | 2017-11-27 | 한국식품연구원 | Weissella koreensis WIKIM54 having anti-allergic disease activity and composition for comprising the same |
| KR101834383B1 (en) * | 2016-11-14 | 2018-03-05 | 한국식품연구원 | Weissella cibaria WIKIM28 having anti-obesity activity and composition for comprising the same |
| WO2020122448A1 (en) * | 2018-12-10 | 2020-06-18 | 주식회사 엠디헬스케어 | Weissella bacteria-derived nanovesicle and use thereof |
| WO2020122484A1 (en) * | 2018-12-10 | 2020-06-18 | 한국식품연구원 | Pharmaceutical composition for preventing or treating cancer, comprising weissella cibaria wikim28 as active ingredient |
| KR20200070989A (en) * | 2018-12-10 | 2020-06-18 | 주식회사 엠디헬스케어 | Nanovesicles derived from Weissella bacteria and Use thereof |
| WO2022045502A1 (en) * | 2020-08-26 | 2022-03-03 | Enterobiome Inc. | Pharmaceutical composition for preventing or treating atopic disease containing faecalibacterium prausnitzii strain |
| WO2022045501A1 (en) * | 2020-08-26 | 2022-03-03 | Enterobiome Inc. | Pharmaceutical composition for preventing or treating atopic disease containing akkermansia muciniphila strain |
| WO2022145960A1 (en) * | 2020-12-28 | 2022-07-07 | 코스맥스 주식회사 | Weissella cibaria strain and use thereof |
| CN115087728A (en) * | 2020-02-05 | 2022-09-20 | Hem制药股份有限公司 | Novel lactobacillus sakei HEM224 strain, and composition for treating inflammation or asthma comprising the same or culture thereof |
| JP7456668B2 (en) | 2020-01-31 | 2024-03-27 | リスキュア・バイオサイエンシーズ・カンパニー・リミテッド | Pharmaceutical composition for preventing or treating cancer containing Weissella cibaria WIKIM28 as an active ingredient |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100074928A (en) * | 2008-12-24 | 2010-07-02 | 한국식품연구원 | Weissella cibaria 148-2 lactic bacteria for functional healthy effect and makgeolli containing the same |
| KR20150031922A (en) * | 2013-09-17 | 2015-03-25 | 충북대학교 산학협력단 | Novel Weissella cibaria JW15 strain and use the same |
-
2015
- 2015-11-12 KR KR1020150159014A patent/KR101667496B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100074928A (en) * | 2008-12-24 | 2010-07-02 | 한국식품연구원 | Weissella cibaria 148-2 lactic bacteria for functional healthy effect and makgeolli containing the same |
| KR20150031922A (en) * | 2013-09-17 | 2015-03-25 | 충북대학교 산학협력단 | Novel Weissella cibaria JW15 strain and use the same |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101834383B1 (en) * | 2016-11-14 | 2018-03-05 | 한국식품연구원 | Weissella cibaria WIKIM28 having anti-obesity activity and composition for comprising the same |
| KR101801697B1 (en) | 2016-12-12 | 2017-11-27 | 한국식품연구원 | Weissella koreensis WIKIM54 having anti-allergic disease activity and composition for comprising the same |
| JP2022511893A (en) * | 2018-12-10 | 2022-02-01 | コリア フード リサーチ インスティテュート | A pharmaceutical composition for preventing or treating cancer containing Wycera cybaria WIKIM28 as an active ingredient. |
| JP2022511913A (en) * | 2018-12-10 | 2022-02-01 | エムディー ヘルスケア インコーポレイテッド | Nanovesicles derived from Weissella bacteria and their uses |
| KR20200070989A (en) * | 2018-12-10 | 2020-06-18 | 주식회사 엠디헬스케어 | Nanovesicles derived from Weissella bacteria and Use thereof |
| CN113164528A (en) * | 2018-12-10 | 2021-07-23 | 韩国食品研究院 | Pharmaceutical composition for preventing or treating cancer comprising Weissella cibaria WIKIM28 as an active ingredient |
| CN113194970A (en) * | 2018-12-10 | 2021-07-30 | Md保健株式会社 | Nano-vesicles derived from Weissella bacteria and uses thereof |
| KR102356626B1 (en) | 2018-12-10 | 2022-01-28 | 주식회사 엠디헬스케어 | Nanovesicles derived from Weissella bacteria and Use thereof |
| WO2020122448A1 (en) * | 2018-12-10 | 2020-06-18 | 주식회사 엠디헬스케어 | Weissella bacteria-derived nanovesicle and use thereof |
| WO2020122484A1 (en) * | 2018-12-10 | 2020-06-18 | 한국식품연구원 | Pharmaceutical composition for preventing or treating cancer, comprising weissella cibaria wikim28 as active ingredient |
| JP7282891B2 (en) | 2018-12-10 | 2023-05-29 | コリア フード リサーチ インスティテュート | Pharmaceutical composition for prevention or treatment of cancer containing Weissella sivaria WIKIM28 as an active ingredient |
| AU2019396103B2 (en) * | 2018-12-10 | 2023-04-13 | Korea Food Research Institute | Pharmaceutical composition for preventing or treating cancer, comprising Weissella cibaria WIKIM28 as active ingredient |
| JP7240031B2 (en) | 2018-12-10 | 2023-03-15 | エムディー ヘルスケア インコーポレイテッド | Nanovesicles derived from Weissella bacteria and uses thereof |
| JP7456668B2 (en) | 2020-01-31 | 2024-03-27 | リスキュア・バイオサイエンシーズ・カンパニー・リミテッド | Pharmaceutical composition for preventing or treating cancer containing Weissella cibaria WIKIM28 as an active ingredient |
| CN115087728A (en) * | 2020-02-05 | 2022-09-20 | Hem制药股份有限公司 | Novel lactobacillus sakei HEM224 strain, and composition for treating inflammation or asthma comprising the same or culture thereof |
| WO2022045501A1 (en) * | 2020-08-26 | 2022-03-03 | Enterobiome Inc. | Pharmaceutical composition for preventing or treating atopic disease containing akkermansia muciniphila strain |
| WO2022045502A1 (en) * | 2020-08-26 | 2022-03-03 | Enterobiome Inc. | Pharmaceutical composition for preventing or treating atopic disease containing faecalibacterium prausnitzii strain |
| WO2022145960A1 (en) * | 2020-12-28 | 2022-07-07 | 코스맥스 주식회사 | Weissella cibaria strain and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101667496B1 (en) | Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising Weissella cibaria WIKIM28 as active ingredient | |
| KR101678317B1 (en) | Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising Lactobacillus sakei WIKIM30 as active ingredient | |
| CN112469812B (en) | Lactobacillus gasseri KBL697 strain and application thereof | |
| KR100772575B1 (en) | External composition for improvement of skin containing herbal extracts | |
| KR102610933B1 (en) | Composition for hair or scalp comprising lysate of Lactobacillus plantarum | |
| KR102119825B1 (en) | A cosmetic composition for maintaining the balance of microbiom in the skin comprising brown rice, grean tea and dandelion fermentation extracts and methode thereof | |
| US11141444B2 (en) | Lactobacillus crispatus KBL693 strain and use thereof | |
| KR102194315B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising centella asiatica fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR102152878B1 (en) | Lactobacillus pentosus strain and composition for improving microbial flora and improving skin varrier comprising the same | |
| KR20110134151A (en) | Agent for treating or preventing skin inflammatory disease comprising cultures of mixed bacteria, cosmetic composition, and pharmaceutical composition | |
| KR100815256B1 (en) | Fermented Rubus coreanus Miq. and the composition containing thereof | |
| KR101831883B1 (en) | Cosmetic composition for anti-itching effect comprising isosecotanapartholide | |
| KR102623439B1 (en) | Anti-fungal composition comprising lactobacillus plantarum | |
| KR101367961B1 (en) | Compositoin for Improving Atopic Dermatitis | |
| KR101433823B1 (en) | External Composition for Skin Using an Extract or a Fraction of Padina arborescens | |
| KR101292944B1 (en) | skin-whitening, anti-bacterial and anti-inflammatory composition comprising a fermented juice of grape | |
| KR102610934B1 (en) | Composition for hair or scalp comprising lysate of Lactobacillus sakei | |
| KR102293592B1 (en) | Skin external composition comprising extract of Martensia jejuensis and functional food comprising extract of Martensia jejuensis | |
| KR20160008942A (en) | A composition comprising fermented Myrothamnus flabellifolius extract and the use thereof | |
| KR101831876B1 (en) | Cosmetic composition for imporving atopic dermatitis comprising isosecotanapartholide | |
| KR101819670B1 (en) | Compositon for prevention or treatment of skin disease | |
| US20110039946A1 (en) | Method of improving atopic dermatological diseases, in which a composition comprising magnolol, honokiol or a combination thereof is administered to a patient with atopic dermatological diseases | |
| KR102180666B1 (en) | Cosmetic Composition for Skin Care Containing Fermented Extracts of Applemint, Citron and Sparassis Crispa | |
| KR102411242B1 (en) | Use of Klebsiella aerogenes to improve skin condition | |
| KR102093879B1 (en) | The cosmetic composition containing root extract of Adenophora stricta for improving skin wrinkle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20191011 Year of fee payment: 4 |